Specialty Pharmacy

The treatment mantra for human immunodeficiency virus (HIV) is almost-perfect lifelong adherence to antiretroviral therapy (ART).

Independent pharmacies will want to consider updating their credit card processing terminals to accept EMV chip cards this fall.

Experimental drug blocks key sites on the virus surface that attach and invade human immune cells.

Shoulder muscle strength found to decrease even in early stage RA patients.

Top news of the week in oncology drug development.

Discovery could lead to treatments that stop cancer recurrence.

For patients with hepatitis C seeking modern treatment options, many health plans force health care professionals use criteria that are clinically unsound.

More than just biological factors can affect patient outcomes.

Top stories of the week on Specialty Pharmacy Times.

Mild psoriasis, severe psoriasis, and psoriatic arthritis may also bring increased comorbidities.

Expansion covers patients who have greater than 30% myeloblasts.

Average time for withdrawals in colonoscopies came in at approximately 8.6 minutes.

Intralesional interleukin-2 shows promise in cutaneous melanoma metastases.

Childhood pneumonia carries a higher risk of chronic bronchitis and other disease-related quality of life issues.

The FDA today approved insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg) to improve glucose control in adults with diabetes.

Veterans who obtain their prescriptions at a VA pharmacy will see their copays remain steady through 2016.

Technology may help improve patient outcomes through enhanced personalized medicine.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses changes ahead for specialty pharmacy patients.

Nanopore technology may soon be adapted for early disease detection.

Investigators question if hepatitis A virus originated in animals.

Researchers examine how immunodeficiency diseases avoid immune system attacks.

Sleep disturbances accounted for a quarter of the variance in fatigue among patients with MS.

Current HIV treatment guidelines are based on data obtained primarily from men.

Findings could eliminate need for weeks of treatments that carry severe side effects.

Hepatitis C incidence rate among HIV-positive men who have sex with men grew three-fold from 1991 to 2010.

Research may help tailor treatments to individual patients.

Usability testing should include at least 15 representative end-user participants.

Kyprolis is for injection in patients with relapsed multiple myeloma.